Isoprenalin Macure (Isoprenaline Hydrochloride)

Isoprenaline is a non‑selective β1 and β2 adrenergic receptor agonist. By binding to these receptors it stimulates adenylate cyclase, raising intracellular cAMP, which increases heart rate and contractility via β1 and relaxes bronchial smooth muscle via β2, producing cardiovascular stimulation and bronchodilation.

The dose is individualized by the prescribing clinician based on the patient’s condition, response, and monitoring parameters. Dosage regimens are determined in a hospital or clinical setting and are not standardized in public literature.

Safety data in pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Unlike selective β2 agonists such as albuterol, isoprenaline stimulates both β1 and β2 receptors, offering simultaneous cardiac stimulation and bronchodilation. This makes it useful in emergencies where both heart rate support and airway opening are needed, but it also carries a higher risk of cardiac side effects compared with β2‑selective agents.

Store at ambient temperature, below 25 °C, in the original sealed container. Protect from light, moisture and extreme temperature fluctuations. Do not freeze the solution. Follow any additional handling instructions provided with the product.

The product is supplied as a sterile solution for intravenous injection. It is administered by a qualified healthcare professional, typically as a continuous infusion or intermittent bolus, with dosage titrated to achieve the desired heart rate or bronchodilation while monitoring vital signs.

Serious adverse events include life‑threatening arrhythmias, myocardial ischemia, severe hypotension, pulmonary edema, and anaphylactic reactions. Continuous cardiac and hemodynamic monitoring is essential during administration to detect and manage these risks promptly.

Patients with known hypersensitivity to isoprenaline or any formulation components, those with uncontrolled tachyarrhythmias, severe hypertension, or recent myocardial infarction should avoid its use. Contra‑indications are determined by the treating physician based on individual clinical assessment.